Tofogliflozin GLP-1 Analogue Combination Trial

• Status: Completed
• Trial end date: 2017-10-01

Summary

An open-label, multicenter study to evaluate 52-week long-term safety, tolerability and efficacy of Tofogliflozin with GLP-1 analogue treatment in type 2 diabetes mellitus.

• Phase: Phase 4

Details

• Lead Sponsor: Kowa Company, Ltd.
• Collaborator: Sanofi
• Treatments: 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol; Glucagon; Glucagon-Like Peptide 1